Trial Profile
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- 26 Jan 2022 Status changed from active, no longer recruiting to completed.
- 06 Dec 2021 Planned End Date changed from 31 Dec 2021 to 23 Dec 2021.
- 06 Dec 2021 Planned primary completion date changed from 31 Dec 2021 to 23 Dec 2021.